CIK 0001817229 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Vor Biopharma Inc.
Sign in to watch- Ticker
- VOR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 811591163
- Phone
- 617-655-6580
- Business address
- 500 BOYLSTON STREET, SUITE 1350, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-09 | PARMAR KUSH Director | Conversion | +1,414,026 | 4,722,848 | ||
| 2021-02-09 | PARMAR KUSH Director | Purchase | +111,111 | $18.00 | $2.0M | 4,833,959 |
| 2021-02-09 | PARMAR KUSH Director | Conversion | +1,414,026 | 1,414,026 | ||
| 2021-02-09 | PARMAR KUSH Director | Purchase | +444,444 | $18.00 | $8.0M | 1,858,470 |
| 2021-02-09 | PARMAR KUSH Director | Conversion · Series A-2 Preferred Stock | −45,000,000 | 0 | ||
| 2021-02-09 | PARMAR KUSH Director | Conversion · Series B Preferred Stock | −19,230,768 | 0 | ||
| 2021-02-09 | PARMAR KUSH Director | Conversion · Series B Preferred Stock | −19,230,768 | 0 | ||
| 2021-02-09 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +1,664,549 | 1,664,549 | ||
| 2021-02-09 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +280,330 | 280,330 | ||
| 2021-02-09 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +3,784,120 | 5,448,669 | ||
| 2021-02-09 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +1,414,026 | 1,694,356 | ||
| 2021-02-09 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +2,848,596 | $18.00 | $51.3M | 8,297,265 |
| 2021-02-09 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +130,970 | $18.00 | $2.4M | 1,825,326 |
| 2021-02-09 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A-2 Preferred Stock | −22,637,875 | 0 | ||
| 2021-02-09 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A-2 Preferred Stock | −3,812,500 | 0 | ||
| 2021-02-09 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series B Preferred Stock | −51,464,036 | 0 | ||
| 2021-02-09 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series B Preferred Stock | −19,230,770 | 0 | ||
| 2021-02-05 | Resnick Joshua Director | Grant or award · Stock Option (right to buy) | +16,900 | 16,900 | ||
| 2021-02-05 | Patterson Matthew R Director | Grant or award · Stock Option (right to buy) | +16,900 | 16,900 | ||
| 2021-02-05 | PARMAR KUSH Director | Grant or award · Stock Option (right to buy) | +16,900 | 16,900 |
Page 17 of 18 · 344 trades